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bjectives The aim of this study was to assess the mid-term safety and efﬁcacy of percutaneous
atent foramen ovale (PFO) closure using a bioabsorbable device (BioSTAR, NMT Medical, Boston,
assachusetts).
ackground Closure of PFO in patients with cryptogenic stroke has proven to be safe and effective
sing different types of permanent devices.
ethods All consecutive patients who underwent percutaneous PFO closure with the bioabsorb-
ble closure device between November 2007 and January 2009 were included. Residual shunt was
ssessed using contrast transthoracic echocardiography.
esults Sixty-two patients (55% women, mean age 47.7  11.8 years) underwent PFO closure. The
n-hospital complications were a surgical device retrieval in 2 patients (3.2%), device reposition in
(1.6%), and a minimal groin hematoma in 6 patients (9.7%). The short-term complications at
-month follow-up (n  60) were a transient ischemic attack in the presence of a residual shunt
n 1 patient and new supraventricular tachycardia in 7 patients (11.3%). At 6-month follow-up
n  60), 1 patient without residual shunt developed a transient ischemic attack and 1 devel-
ped atrial ﬁbrillation. A mild or moderate residual shunt was noted in 51.7%, 33.9%, and 23.7%
fter 1-day, 1-month, and 6-month follow-up, respectively. A large shunt was present in 8.3%,
.4%, and 0% after 1-day, 1-month, and 6-month follow-up.
onclusions Closure of PFO using the bioabsorbable device is associated with a low complication
ate and a low recurrence rate of embolic events. However, a relatively high percentage of mild or
oderate residual shunting is still present at 6-month follow-up. (J Am Coll Cardiol Intv 2010;3:
68–73) © 2010 by the American College of Cardiology Foundation
rom the Department of Interventional Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. The authors have
eported that they have no relationships to disclose.anuscript received February 4, 2010; revised manuscript received June 10, 2010, accepted June 27, 2010.
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969ercutaneous patent foramen ovale (PFO) closure has been
dvocated as an alternative strategy to anticoagulation or
ntiplatelet therapy to prevent recurrence of cryptogenic
troke in young patients. Although a number of series have
uggested that percutaneous closure may be superior, no
ata from randomized trials are available and long-term data
n the effectiveness of transcatheter closure are limited
1–3). Currently, the available closure devices consist of a
etal framework and a permanent, synthetic fabric in which
efect closure is achieved through a combination of me-
hanical closure and fibrous encapsulation. Despite the
fficacy of these devices, potential complications such as
riction lesions, perforations, inflammation, arrhythmias,
nd thrombus formation have been described, even at
ong-term follow-up (4–6). Furthermore, these implants
ill obstruct a potential transseptal access to the left atrium
or future treatment of acquired heart disease.
Therefore, new strategies of PFO closure without a
ermanently implanted device have been explored (7–9).
ne of these new developments is the BioSTAR device
NMT Medical, Boston, Massachusetts), which consists of
metal framework and a totally bioabsorbable matrix. We
eport the mid-term safety and efficacy of percutaneous
FO closure with this novel device.
ethods
atient group. From November 2007 to January 2009, 62
onsecutive patients (55% women, mean age 47.7  11.8
ears) underwent PFO closure with the BioSTAR device
NMT Medical). Most patients were referred by neurolo-
ists, mainly because of cryptogenic stroke or transient
schemic attack (TIA) (93.5%). One patient (1.6%) had
uffered a renal infarction, and 3 patients (4.8%) had
ecompression illness. The study protocol was approved by
he local ethics committee. Patients’ characteristics and
ndications for closure are listed in Table 1.
re-procedure evaluation. All patients underwent compre-
ensive neurologic evaluation. An embolic event was con-
idered to be due to paradoxical embolism when a PFO was
resent and any other obvious cardiac, aortic, or cerebro-
ascular cause was excluded. All patients were assessed by a
tandardized protocol before closure, including contrast
ransthoracic echocardiography (cTTE) with second har-
onic imaging and/or contrast transesophageal echocardi-
graphy. Agitated saline contrast was injected into an
ntecubital vein to demonstrate right-to-left shunt, both at
est and following the Valsalva maneuver. Microbubbles
ere counted in the left atrium within 3 cardiac cycles after
ight heart opacification. As described by Attaran et al. (10),
n acceptable Valsalva maneuver is one in which the
nteratrial septum is seen to shift to the left, most dramat-
cally upon the release phase. The study protocol was based
n a training phase including up to 3 Valsalva maneuver attempts. The patient was asked to press against the closed
lottis for at least 10 s, until septal shifting was observed.
hen, contrast was injected as a rapid bolus that should have
esulted in complete opacification of the right atrium. At that
ime point, the patient was asked to release pressure. If the
ontrast injection or the visualization was suboptimal, the test
as repeated. An atrial septal aneurysm (ASA) was defined as
maximal protrusion of the interatrial septum, or a part of it,
15 mm beyond the plane of the septum. The PFO charac-
eristics are shown in Table 1.
evice description. The BioSTAR device (Fig. 1) is the first
eptal occluder with a totally biodegradable matrix, which is
ounted on the MP35N STARFlex “double-umbrella”
ramework (NMT Medical). The left and right atrial
mbrellas are connected by microsprings, serving a self-
entering mechanism. The matrix consists of an acellular
orcine intestinal collagen layer, coated with a heparin-
enzalkonium-chloride complex, which showed reduced
hrombus formation in animal models (7). Furthermore,
ccelerated neo-endothelialization
nd a lower immune response was
een compared with the STAR-
lex device in a sheep model (11).
he matrix was rapidly incorpo-
ated into the interatrial septum,
eading to a low profile and early
ealing of the defect. Remodeling
f the matrix already started after
0 days and over a period of 2
ears, it is completely replaced by
ost tissue.
The BioSTAR device is avail-
ble in sizes 23, 28, and 33 mm.
ercutaneous PFO closure. As
escribe previously, all proce-
ures were performed in the cardiac catheterization labora-
ory, under general anesthesia and transesophageal echocar-
iography (TEE) guiding in the first 6 patients, and under
ocal anesthesia with intracardiac echocardiographic guiding
hereafter (12). Concomitant fluoroscopic guidance was
sed in all patients. The right femoral vein was used to
dvance a multipurpose catheter, to cross the PFO. The left
emoral vein was used in case of intracardiac echocardiographic
uiding. Intravenous heparin (5,000 IE) and prophylactic
ntibiotics were administered. Delivery and deployment of the
ioSTAR device are similar to that previously described for the
TARFlex device (13,14). All patients were pre-treated with
spirin and clopidogrel.
Successful device implantation was defined as completion
f the procedure without the occurrence of major events
death, device embolization, device malpositioning with
eplacement, or need for surgical intervention). Complica-
ions were divided into major and minor complications
Abbreviations
and Acronyms
ASA  atrial septal
aneurysm
cTTE  contrast
transthoracic
echocardiography
PFO  patent foramen ovale
SVT  supraventricular
tachycardia
TEE  transesophageal
echocardiography
TIA  transient ischemic
attackccording to the classification scheme of Khairy et al. (15).
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970ollow-up evaluation. Within 24 h after closure, an electro-
ardiogram, chest X-ray, and cTTE were performed. All
atients were discharged on aspirin 100 mg once a day for
period of 6 months and clopidogrel 75 mg once a day for
month. Antiplatelet therapy was continued in cases of
ersistence of residual shunting on follow-up cTTE or if
here was another indication. In patients on oral anticoag-
lant therapy before the procedure, clopidogrel was added
or 1 month. Infective endocarditis prophylaxis was recom-
ended for 6 months.
All patients were scheduled for cTTE (with Valsalva
aneuver) at 1 month, 6 months, 1 year, and 2 years to
etermine residual shunting, which was categorized as
ollows: small shunt (30 bubbles in the left atrium),
oderate shunt (30 to 100 bubbles in the left atrium), and
evere shunt (100 bubbles in the left atrium). All echo-
ardiographic examinations were reviewed by 2 independent
hysicians. The 6-month TTE was combined with a visit to
he outpatient clinic where a limited history and physical
xamination were obtained. New-onset supraventricular
achycardias (SVT) were diagnosed by a 12-lead electrocar-
iogram or 24-h Holter monitoring. Patients with sus-
ected recurrent stroke or TIA were re-examined by a
eurologist, and a new imaging study of the brain (com-
Table 1. Baseline Characteristics (n  62)
Mean age  SD, yrs 47.7 11.8
Women 34 (54.8)
Weight, kg 78.3 13.4
BP systolic, mm Hg 130.7 14.8
BP diastolic, mm Hg 78.9 8.4
Risk factors
Smoking 13 (21.0)
Diabetes 3 (4.8)
Arterial hypertension 18 (29.0)
Hypercholesterolemia 21 (33.9)
Family history 20 (32.3)
Coronary artery disease 5 (8.1)
PFO characteristics
RLS Valsalva 62 (100)
RLS spontaneously 24 (38.7)
Aneurysm IAS 25 (40.3)
Indication for closure*
TIA, single 20 (32.3)
TIA, multiple 14 (22.6)
CVA, single 26 (41.9)
CVA, multiple 4 (6.5)
Decompression illness 3 (4.8)
Renal infarction 1 (1.6)
SVT 7 (11.3)
Values are mean SD or n (%). *Six patients had a history of both a TIA and a CVA.
BP blood pressure; CVA cerebrovascular accident, IAS interatrial septum; PFO patent
foramen ovale; RLS  right-to-left shunt; SVT  supraventricular tachycardia; TIA  transient
ischemic attack.uted tomography or magnetic resonance imaging) waserformed. Only definite recurrent cerebrovascular events
ere included in the analysis.
tatistical analysis. Descriptive statistics were used to de-
cribe patients’ characteristics. Continuous variables with
ormal distribution are presented as mean SD. Univariate
tatistical analysis was used to identify risk factors for
esidual shunting and the development of new SVT after
FO closure. Predictors of untoward events were analyzed
y means of the Student t test and Fisher exact test for
ontinuous and categorical variables, respectively. For
ithin-group comparison of proportions, the McNemar
est was used. No formal adjustment for multiple com-
arisons was used. p 0.05 was considered to be statis-
ically significant. All statistical analyses were performed
y using SPSS software version 14.0 for Windows (SPSS
nc., Chicago, Illinois).
esults
rocedural and in-hospital outcome. Device implantation
as successful in 59 patients (95.2%). In 1 patient, a 28-mm
evice was pushed through the PFO in the left atrium,
ecovered into the delivery system, and successfully replaced
y a 33-mm device during the same session. In another
atient, the deployed device could not be retracted into the
elivery system and therefore a femoral vein incision was
eeded to retrieve it. In a 75-year-old man with hyperten-
ion and recurrent TIAs, in which other thromboembolic
ources were firmly excluded, the closure device embolized
o the aorta, was retracted percutaneously by means of a
nare into the femoral artery, and removed by the surgeon.
here was no ASA or any other structural heart disease on
is baseline TTE. Both patients received an Amplatzer
Figure 1. The BioSTAR Device
The biodegradable matrix is mounted on the MP35N STARFlex “double-
umbrella” framework. The left and right atrial umbrellas are connected by
microsprings, serving as a self-centering mechanism.
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971eptal Occluder device (AGA Medical Corp., Plymouth,
innesota) 1 month later. Furthermore, 6 patients (9.7%)
ad a minimal groin hematoma before discharge. There
ere no procedural deaths and none of the procedural
omplications resulted in mid-term sequelae. Procedural
haracteristics are listed in Table 2 and in-hospital compli-
ations in Table 3.
id-term outcome. COMPLICATIONS. During 6-month
ollow-up (n  60), no major complications occurred
Table 3). Eight patients (12.9%) developed a new SVT, 7
f which during the first month. In 2 patients, Holter
onitoring showed nonsustained atrial tachycardia for
hich no further treatment seemed indicated. Five patients
ere successfully treated for a short period with antiarrhyth-
ic drugs and 1 patient with therapy-resistant atrial fibril-
ation required electrical conversion. No predictor for the
evelopment of SVT after PFO closure could be identified
sing univariate analysis.
ECURRENT THROMBOEMBOLIC EVENTS. There were 2
ecurrent TIAs. One TIA occurred within 3 weeks after
FO closure in a patient who was still on dual antiplatelet
Table 2. Procedural Characteristics
Diameter device
23 mm 1 (1.6)
28 mm 53 (85.5)
33 mm 8 (12.9)
Anesthesia 6 (9.6)
Echocardiographic guidance
TEE 6 (9.6)
ICE 56 (90.4)
Radiation dose, gy/cm2 31.1 26.9
Procedural complications
Device reposition 1 (1.6)
Minimal surgical intervention 2 (3.2)
Hospitalization stay, days 2
Values are n (%) or mean SD.
ICE intracardiac echocardiography; TEE transesophageal echocardiography.
Table 3. Complications and Reoccurrence of Stroke
Characteristics In Hospital 1 Month 6 Months
n 62 60 60
Major complications
Minimal surgical intervention 2 (3.2) 0 0
Minor complications
New SVT 0 7 (11.3) 1 (1.6)
Inguinal hematoma 6 (9.7) 0 0
Reposition device 1 (1.6) 0 0
Reoccurrence ischemic event
TIA 0 1 (1.6)* 1 (1.6)†
CVA 0 0 0
Values are n or n (%). *With residual shunt; †without residual shunt.Abbreviations as in Table 1.herapy. There was an atrial septum aneurysm present on
aseline echo and cTTE at discharge revealed a moderate
esidual shunt. An additional TTE a few days after the
vent did not reveal any thrombus on the device; however,
here was still a small residual shunt present. Dual antiplate-
et therapy was continued and at 6-month follow-up, cTTE
id not reveal any residual shunt. A second TIA was noticed
n another patient in the absence of a residual shunt or
hrombus formation. Therefore, the TIA should not be
elated to a cardioembolic source. Both patients clinically
ecovered fully within 12 h after onset of symptoms.
ESIDUAL SHUNT. The percentage of patients with com-
lete occlusion after PFO closure with the BioSTAR device
rogressively increased during follow-up. Complete PFO
losure was achieved in 40%, 62.7%, and 76.3% after 1 day,
month, and 6 months of follow-up, respectively. Mild or
oderate residual shunt was present in 51.7%, 33.9%, and
3.7% after 1 day, 1 month, and 6 months of follow-up and
large shunt was present in 8.3%, 3.4%, and 0% after 1 day,
month, and 6 months of follow-up, respectively (Fig. 2).
nfortunately, no predictor for the presence of a residual
hunt at 6-month follow-up could be identified using
nivariate analysis.
iscussion
s far as we know, this is the largest series of consecutive
atients treated with the BioSTAR device. Our data dem-
nstrate that percutaneous closure with the bioabsorbable
evice can be performed with a high success rate, a low
omplication rate, and that it is associated with a low risk for
troke recurrence during mid-term follow-up. Residual
hunts decline gradually and no large shunts could be
etected 6 months after closure.
%
0
10
20
30
40
50
60
70
1 day FU (n = 62) 1 mo FU (n = 60) 6 mo FU (n = 60)
total
minimal
moderate
severe
p = 0.002
p < 0.001
Figure 2. Residual Shunt Rate by Contrast TTE
This ﬁgure shows the residual shunt rate during follow-up assessed by con-
trast transthoracic echocardiography (TTE). The shunt declines gradually
during follow-up (FU), but there is still 23.7% residual shunting (mild or
moderate) 6 months after defect closure.
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972The major advantage of using a biodegradable device
hould be that only a minimal amount of foreign material
i.e., the framework) remains on the interatrial septum, thus
inimizing the potential risk for future complications.
urthermore, the “natural healing” of the defect and re-
lacement of the device by host tissue should result in an
arlier defect closure and a lower immune response. Those
dvantages were outlined in animal studies and the first in
uman trial showed excellent results regarding safety and
fficacy (7,11,16).
omplications. In the BEST (BioSTAR Evaluation Study)
16), 58 patients (54 PFO, 4 atrial septal defect) with a
ean age of 46  8 years were treated with the BioSTAR
evice. Successful device implantation was achieved in 98%
f the patients; 1 device prolapsed into the right atrium in
n attempt to close an atrial septal defect and was replaced
y an alternative device. In a patient with a PFO and a thick
eptum secundum, a 28-mm device was malpositioned and
uccessfully replaced by a 33-mm device. No other proce-
ural complications were noticed. Our procedural success
ate was 95.2%; 1 device was malpositioned and replaced by
larger one. In this patient, a long tunnel PFO was present
hat was underestimated on echocardiography. Further-
ore, we had 1 arterial device embolization and 1 device
hat had to be removed from the femoral vein after
islodgement from the septum and partial retrieval into the
heath. A possible explanation for these complications is
hat the BioSTAR device is very soft and flexible. Further-
ore, both cases occurred in our learning phase using
ntracardiac echocardiography and therefore could be re-
ated to less adequate visualization. Six of our patients
9.7%) developed a minimal groin hematoma, but none
equired blood transfusion.
Atrial rhythm disturbances are a common short-term
omplication using transseptal devices. Despite the low
rofile and the presumed rapid endothelialization of the
ioSTAR device, the incidence of new SVT in our study
as 12.9%, which is comparable to the frequency of 7% to
5% reported in series with other devices (17,18). We did
ot observe any relationship between the occurrence of SVT
nd device size or the presence of an ASA.
eoccurrence of thromboembolic events. The recurrence
ate of stroke or TIA in our observation is low (3.2%) and
oncordant with findings previously reported. Two system-
tic reviews (1,15) suggest that percutaneous PFO closure is
ore effective than medical treatment regarding secondary
revention of embolic events (recurrence rate: 0% to 4.9%
s. 3.8% to 12% at 1 year). We did not detect any thrombus
n the device in those 2 patients, but we realize that
hrombus assessment with TTE only might be suboptimal.
esidual shunt. The residual shunt rate 6 months after PFO
losure ranges from 8% to 20% (19,20). At 6 months, a mild
r moderate residual shunt was observed in 23.7% of our
tudy population. Direct comparison of the results of these itudies is difficult because different types of devices and
ifferent methodological descriptions were used. Our
ethod of shunt grading showed an excellent interobserver
ariability using cTTE (21). In contrast to other investiga-
ors, who described predictors of residual shunt, such as the
resence of ASA, larger PFO size, and larger device size
22–24), we could not identify predictive factors regarding
esidual shunt. Therefore, we must hypothesize that the
ioSTAR device itself does not “close the door” appropri-
tely. However, rapid endothelialization and defect closure
as seen in a sheep model, the natural healing of the defect
nduced by the matrix of the device may be postponed in
ome patients. Maybe, the role of platelets and platelet-
nhibition is underestimated. When platelets are activated as
result of endothelial damage during PFO closure, they
timulate smooth muscle cell proliferation and migration
nd contribute to the synthesis of connective tissue. Hence,
hen we treat our patients with aspirin and clopidogrel after
FO closure, the formation of neo-endothelium and the
atural healing induced by the BioSTAR device could be
iminished. It is also known that there is a substantial
nterpatient variability regarding inhibition of platelet ag-
regation/activation with aspirin and clopidogrel. To un-
erline our hypothesis, we must state that the sheep in the
nimal model, which did show early endothelialization,
ere not treated with antiplatelet agents.
The 2 other studies (16,25) regarding PFO closure using
he BioSTAR device, report a much lower residual shunt
ate. However, in BEST (16), only moderate and large
hunts were reported. As a result, 4% residual shunting was
een at 6 months using cTTE. In another report (25), no
esidual shunt was observed in 19 patients, 6 months after
FO closure; however, the TTE studies were performed
ithout contrast. On the other hand, 4 of these patients
21%) had a trivial shunt on contrast-transcranial Doppler.
Maybe, our meticulous Valsalva maneuver protocol re-
ulted in a higher amount of residual shunt when compared
o the 2 previous studies.
Despite the high prevalence of residual shunting in our
roup, only 1 patient suffered a reoccurrence of TIA. It is
nown that the persistence of a significant shunt has been
dentified as a risk factor for embolic recurrence. On the
ther hand, it has been outlined that especially small shunts
ay close late; therefore, we will repeat cTTE at 1 year and
years after defect closure.
tudy limitations. First, our patient population was a se-
ected cohort referred for percutaneous PFO closure, and
here may be substantial differences with other series regard-
ng patient selection and implantation technique. Second, it
s a single-center study with a relative small number of
atients and a short follow-up time. Third, during follow-up,
e performed contrast TTE instead of contrast TEE, which is
till defined as the “gold standard” for the detection of
nteratrial shunts. However, TEE is semi-invasive, time-
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973onsuming, and the performance of an adequate Valsalva
aneuver is invariably impaired. Furthermore, contrast TTE
ith second harmonic imaging, as used in our study, seems to
e a very good alternative for TEE as a first-line exam (26).
onclusions
ercutaneous closure of symptomatic PFO using the Bio-
TAR device seems to be safe and efficient, according to the
ow complication rates and the low recurrence rate of
IA/stroke. However, a relative high percentage of residual
hunting is present 6 months after closure. The BioSTAR
evice was developed to extinguish potential complications
hat are inherent to permanent closure devices. We did not
bserve a decrease in atrial rhythm disturbances during the
rst month after closure. Nevertheless, we will perform
ong-term follow-up and hopefully ascertain the true advan-
ages of this new device when it is gradually absorbed over
ime.
eprint requests and correspondence: Dr. Ben J. Van den
randen, St. Antonius Hospital, Koekoekslaan 1, Nieuwegein
435 CM, the Netherlands. E-mail: b.van.den.branden@
ntoniusziekenhuis.nl.
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